Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Skin Neoplasms 1Recurrence 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Propranolol × Dermatologic × Clear all
NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

University Hospital, Geneva

Phase 2 Suspended
450 enrolled
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡